Professor LYU Aiping

Vice-President (Research and Development) cum Dean of Graduate School

Professor LYU Aiping Professor LYU Aiping

Professor Lyu Aiping, a world-leading scientist in aptamer-based translational medicine and drug discovery, is currently Vice-President (Research and Development). Prof Lyu is the Dr. Kennedy Y. H. Wong Endowed Professor in Chinese Medicine at HKBU. He has been elected as a Foreign Member of the Academia Europaea in 2022 in recognition of his sustained academic excellence in systems medicine.

As Vice-President (Research and Development), Professor Lyu is responsible for the development of the University’s overall research strategy, research funding strategy, research infrastructure and postgraduate education. He supports the University in driving multidisciplinary and transdisciplinary research, and leads research teams in securing large extramural research projects.

Professor Lyu obtained his Bachelor’s degree in Chinese Medicine from Jiangxi University of Traditional Chinese Medicine in 1983. He further obtained his Master’s and PhD degrees in Integrative Medicine in Pathology from the China Academy of Traditional Chinese Medicine (now known as the China Academy of Chinese Medical Sciences, CACMS) in 1987 and 1997 respectively.  

Prof Lyu joined the University as the Dean of Chinese Medicine in 2012 and has provided excellent academic leadership for the ongoing development of the School of Chinese Medicine.  Professor Lyu has been at the forefront of promoting transdisciplinary research which integrates traditional Chinese medicine with other biomedical disciplines. Prior to his appointment at HKBU, Professor Lyu was the Executive Director (Legal Representative) of the Institute of Basic Research in Clinical Medicine at China Academy of Chinese Medical Sciences (CACMS).

Prof Lyu’s research interests mainly focus on the translational research in Chinese medicine, including pharmacological and clinical evaluation on rheumatoid arthritis with re-classification and interventions, and the development of new drugs based on Chinese medicines. He is also actively involved in the research on the standardisation of Chinese medicine and the strategic planning and research on the Chinese medicine development in China.